NEW YORK CITY—Results of the largest clinical trial ever conducted in non-metastatic prostate cancer suggest that bicalutamide (Casodex) added to standard care may improve overall survival in men with locally advanced disease undergoing radiotherapy.

CHICAGO—Hypertension that develops during pregnancy places women at higher risk for the condition when they get older, researchers reported at the American Heart Association 2006 Scientific Sessions.

CHICAGO—Two studies suggest that physicians need to pay attention to renal insufficiency in hospitalized patients with cardiac conditions.

NEW YORK—Satraplatin, the first oral platinum analogue, is among the more promising second-line treatments for hormone-refractory prostate cancer (HRPC), a researcher said here at the 2006 Chemotherapy Foundation Symposium.

NEW YORK—A radiolabeled antibody against prostate specific membrane antigen (PSMA) may be a useful treatment for metastatic prostate cancer, preliminary findings suggest.

CHICAGO—Elevated troponin levels are associated with renal insufficiency in patients with heart failure, a new study found.

NEW YORK—Immunotherapy with sipuleucel-T followed by docetaxel chemotherapy may prolong survival in patients with androgen-independent prostate cancer (AIPC), a researcher reported here at the Chemotherapy Foundation Symposium.

NEW YORK—A high-dose oral formulation of calcitriol, called DN 101 and used in combination with docetaxel, is associated with longer survival in men with hormone-refractory prostate cancer (HRPC), according to a recent study.

CHICAGO—Using plasma fasting glucose level and glomerular filtration rate (GFR) in conjunction with the TIMI risk index improves 30-day mortality predictions following acute MI, data show.